After-Hours Movers 12/17: (SCS) (CTAS) (NE) Higher; (FIXX) (PACB) (FDX) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cintas (CTAS) PT Raised to $294 at BofA Securities
December 18, 2019 8:47 AM ESTBofA Securities analyst Gary Bisbee raised the price target on Cintas (NASDAQ: CTAS) to $294.00 (from $291.00) while maintaining a Buy rating following results.
Solid Q2 beat and raise, though Rentals slows modestly... MoreNeoleukin Therapeutics (NLTX) Prices 8.925M Share Offering at $8.40/Sh
December 18, 2019 6:09 AM ESTNeoleukin Therapeutics, Inc. (Neoleukin) (NASDAQ: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the pricing of an underwritten public offering of 8,925,000 shares of its common stock at a price to the public of $8.40 per share. The... More
